If a ruling by a three-judge panel from the US Court of Appeals for the Federal Circuit stands and its regimen is adopted by the FDA – with encouragement from companies – the agency could be doling out tentative-style approvals for biosimilar medicines, letting their manufacturers know six months ahead of market entrance that their products have been licensed.
That's the apparent remedy the court is suggesting in its latest interpretation of the notice of commercial marketing (NCM) provision...